FOR IMMEDIATE RELEASE:

Clinical Neuroscientist, William Z. Potter, M.D., Ph.D., Joins Envoy's Advisory Board

Jupiter, FL – December 14, 2011 – Envoy Therapeutics, Inc., a drug discovery company, today announced that William Z. Potter, MD, Ph.D., has joined the company's scientific advisory board. Previously, Dr. Potter was Vice President of Translational Neuroscience at Merck and, before that, held the position of Head of Early Clinical Development at Eli Lilly. Prior to working in the pharmaceutical industry, he had a distinguished career at the National Institutes of Health, primarily at the National Institute of Mental Health.

Dr. Potter was one of the early architects of the Alzheimer Disease Neuroimaging Initiative, and he continues as an active participant on the Industry Strategic Advisory Board. He also continues to serve as co-chair Emeritus of the National Institutes of Health's Biomarkers Consortium Neuroscience Steering Committee, where he has championed the collaborative development of both biochemical and cognitive measures to enhance drug development for Alzheimer's and other brain diseases. In addition, he serves on the Institute of Medicine Forum on Neuroscience. Dr. Potter has authored over 250 publications in neuroscience.

"Bill has tremendous experience in designing clinical development programs for a broad range of central nervous system disorders," said Stephen Hitchcock, Ph.D., Senior Vice President of Drug Discovery at Envoy. "We're thrilled to have him as an advisor."

"Envoy is pursuing exciting new targets for those psychiatric and neurodegenerative diseases where the medical need is greatest," said Dr. Potter. "I look forward to working with the team to advance as many programs as possible into the clinic."

As a scientific advisor to Envoy, Dr. Potter will provide advice on research and development decisions and program prioritization.

About Envoy Therapeutics
Envoy Therapeutics' mission is to discover new drugs with superior efficacy and fewer side effects than existing treatments. The company's bacTRAP® technology enables the identification of proteins *in vivo* that are produced by specific cell types without requiring the isolation of those cells. The technology is especially powerful in tissues of the brain, where many hundreds of cell types are intermingled. Because therapeutically modulating the activity of a specific cell type has until now been prevented by the inability to determine which proteins are uniquely expressed by that cell type, Envoy brings a new day in drug discovery.

###

Contact:
Robert Middlebrook, Chief Financial Officer
Envoy Therapeutics, Inc.
Tel: 561-210-7705